BioMarin Pharmaceutical Stock Forecast, Price & News

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

Is BioMarin Pharmaceutical a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical or view top-rated stocks.

How has BioMarin Pharmaceutical's stock price been impacted by COVID-19 (Coronavirus)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMRN stock has decreased by 4.5% and is now trading at $82.99.
View which stocks have been most impacted by COVID-19.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BioMarin Pharmaceutical.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.02% and a net margin of 0.86%. The firm's revenue for the quarter was down 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share.
View BioMarin Pharmaceutical's earnings history.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.88 billion, compared to the consensus revenue estimate of $1.85 billion.

What price target have analysts set for BMRN?

15 brokerages have issued twelve-month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $88.00 to $152.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $109.43 in the next year. This suggests a possible upside of 31.9% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:

• Jean-Jacques Bienaimé, Chairman & Chief Executive Officer
• Brian R. Mueller, Chief Financial Officer & Executive Vice President
• Eduardo E. von Pervieux, Chief Information Officer
• Henry J. Fuchs, President-Worldwide Research & Development
• Adora Ndu, VP-World Wide Research & Development

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioMarin Pharmaceutical's key competitors?

Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Repligen (RGEN), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of BMRN's competitors.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.77%), Capital Research Global Investors (9.61%), Janus Henderson Group PLC (2.15%), Geode Capital Management LLC (1.27%), Manning & Napier Group LLC (0.95%) and California Public Employees Retirement System (0.76%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical.

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Alberta Investment Management Corp, Capital Research Global Investors, Neuberger Berman Group LLC, Verition Fund Management LLC, Citigroup Inc., Davide Leone & Partners Investment Co Ltd., Scout Investments Inc., and Two Sigma Advisers LP. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, George Eric Davis, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, and Richard A Meier.
View insider buying and selling activity for BioMarin Pharmaceutical or view top insider-selling stocks.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Fort Washington Investment Advisors Inc. OH, Point72 Asset Management L.P., Rockefeller Capital Management L.P., Marshall Wace LLP, Alliancebernstein L.P., Sphera Funds Management LTD., and Citadel Advisors LLC.
View insider buying and selling activity for BioMarin Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $82.99.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical has a market capitalization of $15.24 billion and generates $1.86 billion in revenue each year. The biotechnology company earns $859.10 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,059 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

Where are BioMarin Pharmaceutical's headquarters?

BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at (415) 506-6700, via email at [email protected], or via fax at 415-382-7889.